Atrium Therapeutics Inc.
RNA | NASDAQ
$8.56
+$0.29 (+3.51%)
Nov 2, 2026, 12:06 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
PE Ratio | -3.49 | -5.01 | -8.68 | n/a |
PEG Ratio | -0.16 | 0.12 | n/a | n/a |
PS Ratio | 9.79 | 11.16 | 293.87 | n/a |
PB Ratio | 1.07 | 0.98 | 1.22 | n/a |
P/FCF Ratio | -4.01 | -4.29 | -12.54 | n/a |
P/OCF Ratio | -4.24 | -4.54 | -13.11 | n/a |
OCF/S Ratio | -130.69 | -158.61 | -2.24K | n/a |
Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.02 |
Quick Ratio | 8.73 | 13.04 | 6.53 | 8.55 |
Current Ratio | 8.73 | 13.04 | 6.53 | 8.55 |
Asset Turnover | 0.01 | 0.07 | 0 | n/a |
Interest Coverage | n/a | n/a | n/a | n/a |
Return on Equity | -9.41% | -7.11% | -23.19% | -3.89% |
Return on Assets | -7.20% | -5.69% | -17.27% | -2.99% |
Return on Invested Capital | -9.02% | -6.33% | -20% | -3.32% |
Dividend Yield | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a |
Gross Profit Margin | 88.58% | 99.23% | 100% | n/a |
Net Profit Margin | -671.97% | -84.71% | -5.6K% | n/a |
Pretax Profit Margin | -671.97% | -84.71% | -5.59K% | n/a |
Operating Profit Margin | -752.93% | -88.01% | -5.59K% | n/a |
FCF Margin | -131.89% | -169.29% | -2.34K% | n/a |
EBITDA Margin | -741.51% | -83.94% | -5.58K% | n/a |
Add to Watchlist
Select watchlists to add or remove RNA